Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dru.

Business Wire • Feb 23, 2026

Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty

Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and lack of near-term catalysts. Management prioritizes debt reduction and margin preservation over growth, with no revenue improvement expected through 2026.

Seeking Alpha • Feb 22, 2026

Organon & Co. (OGN) Q4 2025 Earnings Call Transcript

Organon & Co. (OGN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 12, 2026

Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off

Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelming Women's Health performance, all compounded by ~$8bn in net debt. The dividend was slashed last year to $0.02/quarter, a yield of now ~1%, with capital allocation constrained by high-interest expenses and limited M&A capacity.

Seeking Alpha • Feb 12, 2026

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.

Business Wire • Feb 12, 2026

Organon (OGN) Misses Q4 Earnings and Revenue Estimates

Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Feb 12, 2026

Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Organon (OGN) concluded the recent trading session at $8.2, signifying a -3.98% move from its prior day's close.

Zacks Investment Research • Feb 2, 2026

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.

Business Wire • Jan 29, 2026

Organon Completes Divesture of JADA System to Laborie Medical

OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.

Zacks Investment Research • Jan 29, 2026